Search Within

Gilles Andre Salles

Formats
  1. Meeting Abstract (181)
  2. Journal Article (75)
  3. Research Letter (18)
  4. Review (17)
  5. Editorial (5)
  6. Correspondence (3)
  7. Conference Paper (2)
  8. Guidelines (2)
  9. Book Section (1)
Groups
  1. Department of Medicine (304)
  2. Hematologic Malignancies, Division of (304)
  3. Center for Hematologic Malignancies (164)
  4. Lymphoma (160)
  5. Survivorship Research (116)
  6. Graduate Medical Education (107)

More Groups

People
  1. Maria Palomba (109)
  2. Andrew Zelenetz (74)
  3. Lorenzo Falchi (64)
  4. Anita Kumar (63)
  5. Gunjan Shah (62)
  6. Miguel-Angel Perales (59)

More People

Years
  1. 2025 (21)
  2. 2024 (67)
  3. 2023 (97)
  4. 2022 (69)
  5. 2021 (44)
  6. 2020 (6)
Publications
  1. Blood (126)
  2. Hematological Oncology (28)
  3. Journal of Clinical Oncology (18)
  4. Blood Advances (16)
  5. Haematologica (14)
  6. British Journal of Haematology (9)

More Publications

Publishers
  1. American Society of Hematology (143)
  2. Wiley Blackwell (30)
  3. Elsevier Inc. (20)
  4. American Society of Clinical Oncology (18)
  5. Ferrata Storti Foundation (14)
  6. Nature Publishing Group (14)

More Publishers

Results (304)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Potent CD8+T-cell proliferation and effector differentiation following subcutaneous (SC) mosunetuzumab administration in patients with untreated, high tumor-burden follicular lymphoma (FL)
    Meeting Abstract

    Falchi, L.; Lin, Y. H.; Melendez, L.; Ghione, P.; Owens, C.; Hamlin, P. A.; Lue, J. K.; Epstein-Peterson, Z. D.; Kumar, A.; Palomba, M. L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Brentuximab vedotin-based regimens for older patients with newly diagnosed classical Hodgkin lymphoma -Real world experience
    Meeting Abstract

    Luttwak, E.; Ganesan, N.; Boardman, A. P.; Caron, P.; David, K. A.; Rivas-Delgado, A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Plasma circulating tumor DNA (ctDNA) as an alternative to tissue DNA for genotyping of DLBCL: Results from the POLARIX study
    Meeting Abstract

    Jardin, F.; Raghavan, V.; Tracy, S.; Balasubramanian, S.; Sehn, L. H.; Flowers, C. R.; Morschhauser, F.; Herrera, A. F.; Trněný, M.; Sharman, J. P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Efficacy of subcutaneous epcoritamab vs tisa-cel in R/R LBCL CAR T-naive and CAR T-eligible patients: An indirect comparison
    Meeting Abstract

    Salles, G.; Fox, C. P.; Wang, A.; Sail, K.; Alshreef, A.; Moran, M.; Mutebi, A.; Blaedel, J.; Chirikov, V.; Wang, W. J.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-world response rates across lines of therapy among patients with relapsed/refractory follicular lymphoma
    Meeting Abstract

    Philips, T.; Sehn, L. H.; Wang, A.; Yu, J.; Marchlewicz, E. H.; Kamalakar, R.; Sail, K.; Arnette, D.; Yang, S.; Mutebi, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A multicenter phase 2 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in patients with treatment-naïve, TP53-mutant mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Soumerai, J.; Abramson, J. S.; Barnes, J. A.; Caron, P.; Chabowska, M.; Devlin, M.; Dogan, A.; Falchi, L.; Garcia, R. N.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Subcutaneous (SC) mosunetuzumab (mosun) as first-line therapy for patients (pts) with high tumor-burden follicular lymphoma (FL): First results of a multicenter phase 2 study
    Meeting Abstract

    Falchi, L.; Okwali, M.; Ghione, P.; Owens, C.; Hamlin, P. A.; Lue, J. K.; Epstein-Peterson, Z. D.; Palomba, M. L.; Kumar, A.; Torka, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Treatment outcomes of limited stage grade 3A follicular lymphoma
    Meeting Abstract

    Sarkar, R. R.; Lee, J.; Zhang, Z.; Zelenetz, A. D.; Salles, G.; Yahalom, J.; Imber, B. S.
    Blood (2023)

    Fulltext@MSK | Save
  • Predicting toxicities in older adults with non-Hodgkin lymphoma (NHL) receiving systemic chemotherapy: A prospective geriatric assessment (GA) study
    Meeting Abstract

    Torka, P.; Drill, E.; Ganesan, N.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Dynamics of radiomic features following bridging therapy determine CD19 chimeric antigen receptor (CAR) T-cell therapy outcome
    Meeting Abstract

    Hubbeling, H.; Leithner, D.; Silverman, E. A.; Flynn, J. R.; Devlin, S. M.; Shah, G. L.; Fregonese, B.; Bedmutha, A.; Wills, B.; Tomas, A. A.; more...
    Blood (2023)

    Fulltext@MSK | Save